Recently, Elekta (EKTA-B.ST) announced that its President and CEO, Gustaf Salford, and board of directors have unanimously decided to resign on March 6th.

The board of directors of Yikeda is conducting international recruitment for the position of new CEO. During this period, the board has appointed Jonas Bolander, Executive Vice President, General Counsel, and Group Functional Head with 23 years of experience at Medda, as Acting President and CEO.

01. Net profit decreased by 30%
For the nine months ending January 31, 2025, Elekta achieved revenue of 12.86 billion Swedish kronor and a net profit of 621 million Swedish kronor. Compared to the same period last year, net profit decreased by 30% and revenue decreased by 2%. In the latest Medical Technology Top 100 Report, it ranks 56th in annual revenue.

Dr. Laurent (Larry) Leksell, Chairman of the Board, stated, "Although Elekta's mid-term performance in the third quarter did not meet our expectations, there were still some positive highlights, such as increased orders, strong cash flow, and well controlled costs thanks to the launch of our latest products. However, the Board believes that Elekta now needs new leadership to further increase its focus on improving profitability and strengthen growth by utilizing the most competitive and advanced products in the industry. This will be supported by future product and software releases driven by significant investments in research and development in recent years. I would like to thank Gustaf for all the contributions he has made to Elekta during his 16 years in the company. Among them, he successfully led the company through the COVID-19, promoted the growth of new markets, and accelerated our innovation plan. However, looking ahead to the future, we have agreed to part ways, and we wish him all the best in his future career.

Gustaf Salford said, "This has been a wonderful journey, and I am proud of the Elekta team for providing radiation therapy services to over 300 million people and launching new products in our product portfolio. I want to thank Larry and the board, every employee of Elekta, and our customers for everything they have done. I have confidence in the future of the company, and I believe Elekta will continue to bring hope to all those fighting cancer.

Jonas Bolander said, "After working at Elekta for over 20 years, I firmly believe that we will continue to successfully launch new products and achieve our strategic goals. I look forward to leading this transition period with Elekta's excellent team

02. Global Pioneer in Precision Radiotherapy
Founded in 1972, as a global pioneer in precision radiotherapy, MedTech's 4700 employees worldwide are committed to providing high-precision and personalized radiation therapy to cancer patients worldwide, and benefiting them from it.

The company's headquarters is located in Stockholm, Sweden. The founder of the company is Professor Lars Leksell, the inventor of the world's first gamma knife.

At present, Yikeda's business scope covers more than 120 countries and regions, with advanced technology and innovative solutions applied to over 7000 medical institutions worldwide, providing diagnostic and treatment services to more than 2 million patients annually.

As early as 1982, Medda entered the Chinese market and has now successfully occupied the high-end market of radiotherapy in China. In 2017, China became the second largest radiation therapy equipment production base for Medda outside of Europe, and the products produced were sold worldwide; In 2018, Yikeda Radiotherapy College was officially established. This is the first medical teaching research collaborative development platform for the radiotherapy industry in China. It will promote the integration of cutting-edge radiotherapy technology between China and the international community, strengthen the talent team, and effectively improve the clinical application level of radiotherapy in China from three aspects: innovative development platform, clinical research cooperation, and talent training plan.

At present, among the top 50 radiotherapy equipment in China's top hospitals, Yikeda has a market share of over 50% and is recognized as a leader in radiotherapy in the industry. In China's high-end close range treatment system, Yikeda has a market share of over 70%.

Source: http://qixieke.com/Font/index/detailPage.html?id=3366-19